Holen Sie sich die Stockscreener-App
2.44
1.42%
-0.03
Handel nachbörslich:
2.45
0.01
+0.41%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.47
Offen:
$2.56
24-Stunden-Volumen:
5.60M
Relative Volume:
1.13
Marktkapitalisierung:
$583.31M
Einnahmen:
$303.80M
Nettoeinkommen (Verlust:
$-105.83M
KGV:
-4.5539
EPS:
-0.5358
Netto-Cashflow:
$-93.29M
1W Leistung:
-10.48%
1M Leistung:
-29.01%
6M Leistung:
-14.26%
1J Leistung:
+62.33%
1-Tages-Spanne:
$2.385
$2.59
1-Wochen-Bereich:
$2.385
$3.27
52-Wochen-Spanne:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.44 | 590.49M | 303.80M | -105.83M | -93.29M | -0.5358 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - Yahoo Finance
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - simplywall.st
H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026 - Meyka
Esperion Therapeutics, Inc (ESPR) Misses Q4 EPS Estimates - AlphaStreet
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.1%Time to Sell? - MarketBeat
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics Reports Strong 2025 Revenue Growth, Expands Global Cardiovascular Franchise and Advances New Therapies - Minichart
Esperion Therapeutics, Inc (ESPR) Reports Q4 Earnings - AlphaStreet
Esperion Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Esperion Q4 2025 slides: 38% sales growth, $4.6B CHF opportunity - Investing.com Nigeria
ESPR: Record revenue growth and strategic expansion set the stage for sustained momentum in 2026 - TradingView
Earnings call transcript: Esperion Therapeutics Q4 2025 misses EPS but sees revenue surge - Investing.com Canada
Esperion Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ESPR) 2026-03-10 - Seeking Alpha
Esperion shares jump 8% on revenue beat, acquisition plans - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Esperion Q4 2025 Earnings: $61.8M Profit, $168.4M Revenue Exceeds EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates - Yahoo Finance
Esperion Therapeutics Swings to Q4 Earnings, Revenue Rises - marketscreener.com
Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27 - marketscreener.com
ESPERION THERAPEUTICS ($ESPR) Releases Q4 2025 Earnings - Quiver Quantitative
Esperion Therapeutics: Fourth Quarter Earnings Overview - Bitget
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart.com
Esperion Therapeutics Q4 revenue jumps 144% on US product strength - TradingView
Esperion Reports 21% Revenue Growth in FY25, Announces Strategic Acquisition of Corstasis Therapeutics - Quiver Quantitative
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.2%What's Next? - MarketBeat
Esperion Therapeutics Q4 2025 earnings preview - MSN
United StatesArnold & Porter Advises Corstasis In Sale To Esperion - Mondaq
A Peek at Esperion Therapeutics's Future Earnings - Benzinga
Market Rankings: Can Esperion Therapeutics Inc outperform under higher oil pricesPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Esperion settles litigation with Accord Healthcare - MSN
Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet - RTTNews
/C O R R E C T I O N -- HLS Therapeutics Inc./ - Yahoo Finance
Royce & Associates LP Takes Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - The Globe and Mail
Esperion Therapeutics Hits Day Low of $2.83 Amid Price Pressure - Markets Mojo
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Finviz
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1%Should You Sell? - MarketBeat
Ann Arbor pharmaceutical company to pay $75M in deal for new drug - Crain's Detroit Business
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):